A MULTICENTER, SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF AN IV LOADING DOSE FOLLOWED BY SC ADMINISTRATION OF BIMEKIZUMAB (UCB4940) IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS.
Latest Information Update: 22 Aug 2018
At a glance
- Drugs Bimekizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 25 Jul 2018 Status changed from recruiting to discontinued.
- 25 Jul 2018 Trial has been discontinued in Poland. (End Date-2018-05-30)
- 16 Jun 2018 This study has been discontinued in Spain.